Skip to main content
. 2010 Dec 3;31(12):1604–1610. doi: 10.1038/aps.2010.171

Figure 5.

Figure 5

α-TOS acted synergically with hrTRAIL in the induction of apoptosis in erbB2-expressing breast cancer cells. MCF7 (A) and MDA-MB-453 (B) cells were treated with hrTRAIL (10 ng/mL or 30 ng/mL) and/or α-TOS (50 μmol/L) for the indicated durations. When we detected synergy between hrTRAIL and α-TOS, both reagents were added to the cells at same time. Apoptosis was assessed using the annexin V method and evaluated based on the percentage of annexin V-positive cells scored by FACS analysis. Data are shown as the mean values±SD (n=5−8). The symbol “b” indicates a significant difference in apoptosis in cells exposed to hrTRAIL+α-TOS vs cells exposed to hrTRAIL or α-TOS (bP<0.05). (C) MDA-MB-453 cells were evaluated by Western blotting for the expression of erbB2 after treatment with erbB2/siRNA for 24 and 48 h. (D) Induction of apoptosis in control MDA-MB-453 cells (1) and cells pretreated with non-silencing siRNA (2) or erbB2/siRNA (3) and exposed to 30 ng/mL hrTRAIL for 48 h. “e” Indicates a significant difference in hrTRAIL-induced apoptosis in cells pretreated with erbB2/siRNA vs cells pretreated with non-silencing siRNA (eP<0.05). The data are derived from three independent experiments and are presented as the mean values±SD.